Loiasis, or African eye worm, is a chronic parasitic infection affecting approximately 20 million individuals(1) worldwide in endemic areas, with sporadic cases reported elsewhere. We report the case of a 21-year-old Cameroonian woman who has been a student and resident in France for one year, with no travel history to endemic regions since her arrival. In September 2023, she presented to the ophthalmic emergency department of Brest University Hospital with discomfort and itching in her left eye. Visual acuity was 10/10 in the right eye and 7/10 in the left eye. Examination revealed a mobile translucent cord beneath the nasal-inferior conjunctiva of the left eye (figure 1 and video in supplementary file). The anterior chamber was quiet, and the right eye examination was unremarkable. In this case, due to the patient's anxiety and discomfort, short general anesthesia was administered for the extraction procedure. One living nematode was extracted. Parasitological examination identified a male Loa loa of 31 mm length (figure 2). While the patient had no eosinophilia, diurnal microfilarial serology was positive, with a blood smear showing microfilariae <0.05/mL. No other locations of Loa loa were found. Following a three-week wait for medication delivery, the patient was hospitalized in infectious diseases department to monitor diethylcarbamazine treatment tolerance. Treatment began with 1/32 tablet of 100 mg, progressively doubled to an effective dose of 200 mg twice daily from day 8. The total diethylcarbamazine duration was 28 days. The treatment was well-tolerated, with mild headaches managed by acetaminophen. Ophthalmic follow-up was uneventful. This case underscores the need to consider loiasis in at-risk individuals in non-endemic areas, highlighting interdisciplinary collaboration with microbiologists and infectiologists and reconsideration of treatment availability in non-endemic areas. Loiasis, currently not on the WHO list of neglected tropical diseases, warrants attention, as recent studies show a 14.5% attributable mortality risk(2), which could change thanks to the MorLo projects.